Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03654833 | Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma(MiST) | completed | Phase 2 | 186 | University of LeicesterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 61 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 |
| clinicaltrials |
| NCT00428285 | Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men | completed | Phase 2 | 20 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04896073 | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05348668 | Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 78 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05758116 | Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients | completed | Phase 2 | 5 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06812871 | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis | completed | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06907641 | Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy(Co-PSMA) | completed | Phase 2 | 50 | St Vincent's Hospital, SydneyOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01677884 | Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy(BEVIAC) | completed | Phase 2 | 10 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT02227199 | Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma(BV-ICE) | completed | Phase 1 / Phase 2 | 45 | University of WashingtonOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03409432 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | completed | Phase 2 | 26 | John ReneauOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | completed | Phase 2 | 82 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT04924101 | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) | completed | Phase 2 | 122 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Aug 13, 2026 | clinicaltrials |
| NCT05407675 | A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 13, 2026 | clinicaltrials |
| NCT06251050 | A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy | completed | Phase 1 / Phase 2 | 175 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00936858 | RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01063647 | Dose-range Finding Treosulfan-based Conditioning | completed | Phase 1 / Phase 2 | 56 | medac GmbHINDUSTRY | 4 | Aug 12, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT02657551 | A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04762888 | 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer | completed | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04769388 | Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib(FLAME) | completed | Phase 2 | 80 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06139211 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 66 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06289049 | Heavy Strength Training in Head and Neck Cancer Survivors(LIFTING2) | completed | Phase 2 | 37 | University of AlbertaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02581930 | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03495882 | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | completed | Phase 1 / Phase 2 | 175 | Agenus Inc.INDUSTRY | 9 | Aug 11, 2026 | clinicaltrials |
| NCT03587662 | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04354662 | Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer | completed | Phase 2 | 51 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04827719 | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS | completed | Phase 2 | 38 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05478239 | ArtemiCoffee in Patients With Rising PSA | completed | Phase 2 | 20 | Zin W MyintOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04415944 | Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy(HIPEC) | completed | Phase 2 | 10 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06145412 | A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00461955 | Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation(Expansion) | completed | Phase 2 | 13 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02071901 | Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | Phase 2 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02206984 | Endocrine Response in Women With Invasive Lobular Breast Cancer | completed | Phase 2 | 201 | Priscilla McAuliffeOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03416153 | Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | completed | Phase 2 | 91 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT03573024 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | completed | Phase 2 | 36 | University of Colorado, DenverOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04145349 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | completed | Phase 1 / Phase 2 | 30 | Eli Lilly and CompanyINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT04386967 | OH2 Injection in Solid Tumors | completed | Phase 1 / Phase 2 | 44 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT00911560 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | completed | Phase 1 / Phase 2 | 374 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 52 | Jennerex BiotherapeuticsINDUSTRY | 3 | Aug 5, 2026 | clinicaltrials |
| NCT01494155 | Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02296684 | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 67 | Washington University School of MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03026062 | Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04827862 | RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy | completed | Phase 2 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05235074 | OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 40 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06006403 | Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | completed | Phase 1 / Phase 2 | 5 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials